Home | Products | Lentivirus Production | Virus Packaging | pPACK-SPIKE™ N501Y, SARS-CoV-2 “S” Pseudotype – N501Y Mutant – Lentivector Packaging Mix

pPACK-SPIKE™ N501Y, SARS-CoV-2 “S” Pseudotype – N501Y Mutant – Lentivector Packaging Mix

Safely develop SARS-CoV-2 vaccines and antivirals using lentiviral particles pseudotyped with the N501Y Spike protein variant found in mouse-adapted virus.

  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 N501Y “S” protein in place of VSV-G envelope protein
  • Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
Catalog Number
Description
Size
Price
Quantity
Add to Cart
CVD19-560A-1
pPACK-SPIKE N501Y, SARS-CoV-2 “S” Pseudotype – N501Y Mutant – Lentivector Packaging Mix
10 Reactions
$ 650
CVD19-570A-1
pPACK-SPIKE N501Y, SARS-CoV-2 “S” Pseudotype – N501Y Mutant – Lentivector Packaging Mix (XL)
25 Reactions
$ 1295
CVD19-575A-KIT
pPACK-SPIKE N501Y Combo Kit, includes Cat# CVD19-560A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1)
1 Kit
$ 1095

Overview

Safely study SARS-CoV-2 interactions 

Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE N501Y SARS-CoV-2 “S” Pseudotype – N501Y Mutant – Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 N501Y Spike glycoprotein. This variant is found in mouse-adapted SARS-CoV-2 and is used in mouse models of infection [1], making pPACK-SPIKE N501Y the ideal reagent for vaccine and antiviral drug discovery projects.

Based on SBI’s highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 N501Y Spike protein [2] replacing the standard VSV-G envelope protein, the pPACK-SPIKE N501Y Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, N501Y “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE N510Y studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.

  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized, truncated SARS-CoV-2 N501Y “S” protein [1, 2] in place of VSV-G envelope protein
  • Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control

pPACK-SPIKE N501Y SARS-CoV-2 “S” Pseudotype -N501Y Mutant – Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all of the available pPACK-SPIKE S protein variants:

Catalog NumberProduct DescriptionSpike protein mutation
CVD19-500A-1pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging MixOriginal Wuhan-Hu-1 strain
CVD19-530A-1pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging MixD614G
CVD19-560A-1pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging MixN501Y
CVD19-580A-1pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging MixK417N, E484K, & N501Y
CVD19-600A-1pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging MixK417N, E484K, N501Y, & D614G
CVD19-590A-1pPACK-SPIKE B.1.1.7, SARS-CoV-2 "S" Pseudotype - B.1.1.7 (UK) Variant - Lentivector Packaging MixΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
CVD19-610A-1pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging MixS13I, W152C, L452R, & D614G
CVD19-620A-1pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging MixΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L
CVD19-630A-1pPACK-SPIKE P1, SARS-CoV-2 "S" Pseudotype - P1 Variant - Lentivector Packaging MixL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
LV550A-1pPACK-BALD™ (Negative Control Packaging Mix)An envelope protein-free negative control for pPACK-SPIKE

References

  1. Gu H, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020 Sep 25;369(6511):1603. doi: 10.1126/science.abc4730. PMCID: PMC7574913.
  2. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.

How It Works

pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.

Supporting Data

To see data generated using the pPACK-SPIKE with the S protein from the original Wuhan-Hu-1 strain, visit the pPACK-SPIKE  page.

Have Questions?

A System Biosciences technical expert is happy to help!

(888) 266-5066 or Contact Us

Sign up to receive technical advice and exclusive deals directly to your inbox.